Expand URGN Menu
URGN MENU

URGN Latest Press Releases

-- December 5, 2025 --

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 8:00 AM

-- November 25, 2025 --

UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference Globe Newswire 8:00 AM

-- November 6, 2025 --

UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial Globe Newswire 7:58 AM

-- November 4, 2025 --

UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference Globe Newswire 8:00 AM

-- October 30, 2025 --

UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025 Globe Newswire 8:00 AM

-- October 27, 2025 --

Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI Effective January 1, 2026 Globe Newswire 8:00 AM

-- October 2, 2025 --

ZUSDURI Clinical Review Published in Reviews in Urology Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer Globe Newswire 8:00 AM

-- September 8, 2025 --

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 8:00 AM

-- August 21, 2025 --

UroGen Pharma to Present at Upcoming Investor Conferences Globe Newswire 8:00 AM

-- August 7, 2025 --

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI and Reports Second Quarter 2025 Financial Results Globe Newswire 8:00 AM

-- August 5, 2025 --

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer Globe Newswire 8:00 AM

-- July 29, 2025 --

UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025 Globe Newswire 8:00 AM

-- July 28, 2025 --

UROGEN FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors in to Inquire About Their Rights in Class Action Lawsuit Globe Newswire 10:45 AM
UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes